Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)
Condition: HIV Infections
Intervention: Biological: rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
3 Completed Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA009-00-VP;   Biological: VRC-HIVADV014-00-VP
4 Active, not recruiting Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: Ad26.ENVA.01 (rAd26);   Biological: Placebo Vaccine
5 Completed Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV vCP1521;   Biological: ALVAC HIV-1 vCP1521
6 Completed A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV (vCP1452);   Biological: LIPO-5
7 Completed A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers
Condition: HIV Infections
Interventions: Biological: APL 400-047;   Biological: ALVAC-HIV MN120TMG (vCP205);   Drug: Sargramostim
8 Active, not recruiting Antigenic Competition in HIV Preventive Vaccines
Condition: HIV Infections
Interventions: Biological: rAd5 Gag-Pol Env A/B/C;   Biological: rAd5 Gag-Pol
9 Unknown  Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers
Condition: HIV Infections
Intervention: Biological: SCBaL/M9
10 Completed Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
11 Completed Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP
12 Active, not recruiting Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA-016-00-VP;   Biological: VRCHIVADV014-00-VP
13 Completed Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVADV014-00-VP
14 Completed Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC(2)120(B,MN)GNP (vCP1452)
15 Completed Phase 1 Safety Study of Two Experimental HIV Vaccines
Conditions: AIDS Vaccines;   HIV Infections;   HIV-1
Interventions: Drug: VRC-HIVADV027-00-VP;   Drug: VRC-HIVADV038-00-VP
16 Completed A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
Condition: HIV Infections
Interventions: Biological: Aluminum hydroxide;   Biological: QS-21;   Biological: rgp120/HIV-1MN
17 Completed A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals
Condition: HIV Infections
Interventions: Biological: gp160 Vaccine (Immuno-AG);   Biological: rgp120/HIV-1IIIB;   Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2;   Biological: HIVAC-1e
18 Completed Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: AVX101;   Other: placebo
19 Completed HIV-1 Vaccine Test in Uninfected Adult Volunteers
Condition: Healthy
Intervention: Drug: VCR-HIVDNA006-00-VP
20 Completed Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-1 gag DNA;   Biological: HIV-1 gag DNA plus IL-12 DNA adjuvant;   Biological: CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine);   Biological: Sodium chloride injection (0.9%)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years